跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 19 条关于
“MR4.5”
全部
19
临床试验
11
药物
0
机构
0
资讯
8
去年
Novartis' Scemblix Shows Sustained Superiority in Newly Diagnosed CML Patients
去年
Early Molecular Milestones Critical for Treatment-Free Remission Success in Chronic Myeloid Leukemia
8年前
Final 5-Year Results of the Phase 2 PACE Trial for CML and Ph+ ALL Patients
去年
Ruxolitinib Plus TKI Therapy Shows Promise in Chronic Myeloid Leukemia
去年
ASC2ESCALATE Trial Shows Promising Results for Asciminib in Second-Line CML Treatment
去年
FDA Approves Asciminib (Scemblix) as First-Line Treatment for Ph+ Chronic Myeloid Leukemia
去年
Ponatinib Shows Superior Survival Outcomes in Ph+ ALL Patients with Persistent MRD After Induction
4个月前
Asciminib Shows Sustained Efficacy in Heavily Pretreated CML Patients with 39% Achieving Major Molecular Response